dostarlimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
primate origin	5451	2022215-59-2

Description:

Molecule	Description
Molfile Synonyms: dostarlimab dostarlimab-gxly jemperli TSR-042 WBP-285	Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

dostarlimab
dostarlimab-gxly
jemperli
TSR-042
WBP-285

Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 21, 2021	EMA	GlaxoSmithKline (Ireland) Limited
April 22, 2021	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	60.74	49.60	22	209	151135	63337656

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FF07	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000191259	Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC	N0000191260	Programmed Death Receptor-1 Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Recurrent or advanced endometrial cancer	indication	254878006	DOID:2871

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Programmed cell death protein 1	Membrane receptor	Q15116	PDCD1_HUMAN	ANTIBODY BINDING	Kd	8.82		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
D11366	KEGG_DRUG
P0GVQ9A4S5	UNII
C5242455	UMLSCUI
CHEMBL4298124	ChEMBL_ID
DB15627	DRUGBANK_ID
11518	IUPHAR_LIGAND_ID
018705	NDDF
1156877005	SNOMEDCT_US
1156880006	SNOMEDCT_US
4040426	VANDF
4040427	VANDF
2539967	RXNORM
345588	MMSL
39478	MMSL
d09732	MMSL
C000719628	MESH_SUPPLEMENTAL_RECORD_UI
10787	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Jemperli	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0898	INJECTION	50 mg	INTRAVENOUS	BLA	28 sections
Jemperli	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0898	INJECTION	50 mg	INTRAVENOUS	BLA	28 sections
Jemperli	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0898	INJECTION	50 mg	INTRAVENOUS	BLA	28 sections